

DEPARTMENT OF PUBLIC HEALTH 559-675-7893

1604 Sunrise Avenue Madera, CA 93638

SARA BOSSE Public Health Director

SIMON PAUL, M.D. Health Officer

Become a COVID Vaccine Provider

Vaccine enrollment Information

If you need assistance enrolling, contact Eduardo Herrera at Eduardo. Herrera@maderacounty.com.

Key reasons to enroll in the program now:

- Be prepared: when vaccines are approved for children they will be required for school and demand will be high.
- There are fewer barriers to enroll.
- Pfizer is easier to store! It can be stored up to 10 weeks in a routine refrigerator.
- Pfizer now comes in smaller standard order sizes and is also available through small orders.
- Get reimbursed for \$40 administration fee and no-cost vaccines.
- You don't need to be enrolled in VFC or offer Medi-Cal services
- Your strong recommendation as a provider is one of the most important factors in your patients' decision to get vaccinated.
- Providers in the Vaccines for Children Program are already set up for proper storage and administration.

Provider Onboarding Journey

Steps to enroll-Contact us if you need assistance

- 1. Organization: Designate Staff to fill organization and locations coordinator roles
- 2. **Organization Coordinator**: Ensure your organization will meet all program requirements by reviewing **CDC Provider Agreement**
- **3. Organization Coordinator**: Enroll clinic locations with local IIS. (If not already enrolled.)
- 4. Organization Coordinator: Create Account within myCAvax and complete required trainings
- 5. Organization Coordinator: Complete Section A: Enroll Parent organization. CEO/CMO e-signs
- 6. Organization Coordinator: Invite location coordinators to complete Section B for provider locations
- 7. Location Coordinator: Create account and complete required trainings in myCAvax
- 8. Location Coordinator: Complete Section B: Enroll Provider Locations; Vaccine Coordinator e-signs.

^{*}CDPH reviews and approves location applications in 3-5 business days.

Additional help for enrollment:

Type of Support		Description
	COVID-19 Provider Call Center	The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution. • Email: covidcallcenter@cdph.ca.gov • Phone: (833) 502-1245, Monday through Friday from 8AM–6PM
	Enrollment Support	For Provider enrollment support, please contact myCAvax Clinic Operations at • Email: myCAvaxInfo@cdph.ca.gov
	myCAvax Help Desk	Dedicated staff provides up-to-date information and technical support on the myCAvax system. Email: myCAvax.HD@Accenture.com Phone: (833)-502-1245, Option 2, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM-1PM
		For training opportunities: https://eziz.org/covid/education/
ф [*]	My Turn Clinic Help Desk	For onboarding support (those in the process of onboarding): myturnonboarding@cdph.ca.gov For technical support with My Turn Clinic for COVID-19 and flu vaccines: myturn.Clinic.HD@Accenture.com or (833) 502-1245, Option 4, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM–1PM.
		For job aids and demo and training opportunities: https://eziz.org/covid/myturn/

Covid Testing

Many clinics and providers have established connections with laboratories to carry out COVID testing.

- If you need information on which labs can provide this service, please contact <u>Eduardo.Herrera@maderacounty.com</u>.
- In addition, if your office or organization is interested in providing rapid antigen testing on site, and needs testing kits contact us at MCDPH.
- Availability is difficult to predict, however, both CLIA waived test kits for patient care and at times home test kits for staff are available for distribution.

Covid Treatment Information

What's New in COVID Treatment



PATIENT DISPOSITION

Does Not Require

Hospitalization or

Supplemental Oxygen

PANEL'S RECOMMENDATIONS

All patients should be offered symptomatic management (AIII).

For patients who are at high risk of progressing to severe COVID-19^a (treatments are listed in order of preference based on efficacy and convenience of use):

- Ritonavir-boosted nirmatrelvir (Paxlovid)^{b,c} (Alla)
- Sotrovimab^d (Alla)
- Remdesivirc,e (Blla)
- + bebtelovimab (a new MAB)
- Molnupiravir^{c,f} (Clla)

The Panel recommends against the use of dexamethasone or other systemic corticosteroids in the absence of another indication (AIII).⁹

COVID-19 Treatment Guidelines Panel. The COVID-19 Treatment Guidelines Panel's Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19. National Institutes of Health. Updated January 19, 2022. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-

Who should get treatment?

Who should get Outpatient COVID Treatments?

Immunecompromised

Elderly, unvaxxed/unboosted

Elderly with risk factors

https://www.covid19treatmentguidelines.n ih.gov/management/clinicalmanagement/nonhospitalized-adults-therapeutic-management/

Table A. Patient Risk Groups for Prioritizing the Use of Anti-SARS-CoV-2 Therapy

Tier	Risk Group	
1	Immunocompromised individuals who are not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of their vaccine status (see Immunocompromising Conditions below); or Unvaccinated individuals who are at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors)	
2	Unvaccinated individuals who are at risk of severe disease and who are not included in Tier 1 (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors)	
3	Vaccinated individuals who are at high risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with clinical risk factors) Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely to be at higher risk for severe disease; patients who have not received a booster dose and who are within this tier should be prioritized for treatment.	
4	Vaccinated individuals who are at risk of severe disease (anyone aged 265 years or anyone aged <65 with clinical risk factors) Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely to be at higher risk for severe disease; patients who have not received a booster dose and who are within this tier should be prioritized for treatment.	

CDPH maintains a detailed site for both patients and providers, with links to detailed prescribing information. For up-to-date information on COVID treatments and eligibility criteria in California visit: https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Treatments.aspx Or scan the QR code below:



For more information on treatment availability visit: https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/. Or by scanning the QR code below:



Worried about Drug Interactions?

The website https://www.covid19-druginteractions.org/checker makes checking for drug interactions simple. (Google "Liverpool COVID interactions"-the site is run by the university of Liverpool).

For further information on available Covid treatments:

Google "phe therapeutics" and there is a link to the side-by-side overview and other resources:

https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/Side-by-Side-Overview-of-mAbs-Treatment.aspx?ACSTrackingID=USCDC_511-DM72818&ACSTrackingLabel=HAN%20461-%20COCA%20Subscribers&deliveryName=USCDC_511-DM72818 or by scanning the QR code below:

